Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Clinical trial NCT01926782 · COMPLETED
Trial details
- NCT number
- NCT01926782
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-01
- Primary completion
- 2014-09-01
- Enrollment
- 803
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.